Sang-Young Kim1, Marc J Kaufman2, Bruce M Cohen3, J Eric Jensen4, Joseph T Coyle5, Fei Du1, Dost Öngür6. 1. McLean Imaging Center, McLean Hospital, Harvard Medical School, Belmont, Massachusetts; Psychotic Disorders Division, McLean Hospital, Harvard Medical School, Belmont, Massachusetts. 2. McLean Imaging Center, McLean Hospital, Harvard Medical School, Belmont, Massachusetts; Translational Imaging Laboratory, McLean Hospital, Harvard Medical School, Belmont, Massachusetts. 3. Program for Neuropsychiatric Research, McLean Hospital, Harvard Medical School, Belmont, Massachusetts. 4. Deceased. 5. Laboratory for Psychiatric and Molecular Neuroscience, McLean Hospital, Harvard Medical School, Belmont, Massachusetts. 6. Psychotic Disorders Division, McLean Hospital, Harvard Medical School, Belmont, Massachusetts. Electronic address: dongur@partners.org.
Abstract
BACKGROUND: Accumulating evidence suggests the involvement of abnormal glutamateric neurotransmission and N-methyl-D-aspartate receptor hypofunction in the pathophysiology of psychotic disorders. The purpose of this study was to quantify in vivo glutamate (Glu) and glycine (Gly) levels in patients with first-episode psychosis as well as age-matched healthy control subjects with magnetic resonance spectroscopy (MRS). METHODS: The subjects were 46 patients with first-episode psychosis (20 with a schizophrenia spectrum disorder, 26 with bipolar disorder) and 50 age-matched healthy control subjects. Glu and Gly levels were measured in vivo in the anterior cingulate cortex and posterior cingulate cortex of the subjects by using the echo time-averaged proton MRS technique at 4T (i.e., modified point resolved spectroscopy sequence: 24 echo time steps with 20-ms increments). Metabolite levels were quantified using LCModel with simulated basis sets. RESULTS: Significantly higher Glu and Gly levels were found in both the anterior cingulate cortex and posterior cingulate cortex of patients with first-episode psychosis as compared with healthy control subjects. Glu and Gly levels were positively correlated in patients. Patients with a schizophrenia spectrum disorder and bipolar disorder showed similar abnormalities. CONCLUSIONS: Our findings demonstrate abnormally elevated brain Glu and Gly levels in patients with first-episode psychosis by means of echo time-averaged proton MRS at 4T. The findings implicate dysfunction of N-methyl-D-aspartate receptor and glutamatergic neurotransmission in the pathophysiology of the acute early phase of psychotic illnesses.
BACKGROUND: Accumulating evidence suggests the involvement of abnormal glutamateric neurotransmission and N-methyl-D-aspartate receptor hypofunction in the pathophysiology of psychotic disorders. The purpose of this study was to quantify in vivo glutamate (Glu) and glycine (Gly) levels in patients with first-episode psychosis as well as age-matched healthy control subjects with magnetic resonance spectroscopy (MRS). METHODS: The subjects were 46 patients with first-episode psychosis (20 with a schizophrenia spectrum disorder, 26 with bipolar disorder) and 50 age-matched healthy control subjects. Glu and Gly levels were measured in vivo in the anterior cingulate cortex and posterior cingulate cortex of the subjects by using the echo time-averaged proton MRS technique at 4T (i.e., modified point resolved spectroscopy sequence: 24 echo time steps with 20-ms increments). Metabolite levels were quantified using LCModel with simulated basis sets. RESULTS: Significantly higher Glu and Gly levels were found in both the anterior cingulate cortex and posterior cingulate cortex of patients with first-episode psychosis as compared with healthy control subjects. Glu and Gly levels were positively correlated in patients. Patients with a schizophrenia spectrum disorder and bipolar disorder showed similar abnormalities. CONCLUSIONS: Our findings demonstrate abnormally elevated brain Glu and Gly levels in patients with first-episode psychosis by means of echo time-averaged proton MRS at 4T. The findings implicate dysfunction of N-methyl-D-aspartate receptor and glutamatergic neurotransmission in the pathophysiology of the acute early phase of psychotic illnesses.
Authors: Alice Egerton; Stefan Brugger; Marie Raffin; Gareth J Barker; David J Lythgoe; Philip K McGuire; James M Stone Journal: Neuropsychopharmacology Date: 2012-07-04 Impact factor: 7.853
Authors: Lisa A Bartolomeo; Andrew M Wright; Ruoyun E Ma; Tom A Hummer; Michael M Francis; Andrew C Visco; Nicole F Mehdiyoun; Amanda R Bolbecker; William P Hetrick; Ulrike Dydak; John Barnard; Brian F O'Donnell; Alan Breier Journal: Int J Psychophysiol Date: 2019-05-23 Impact factor: 2.997
Authors: Marin Veldic; Vincent Millischer; John D Port; Ada Man-Choi Ho; Yun-Fang Jia; Jennifer R Geske; Joanna M Biernacka; Lena Backlund; Susan L McElroy; David J Bond; J Carlos Villaescusa; Michelle Skime; Doo-Sup Choi; Catharina Lavebratt; Martin Schalling; Mark A Frye Journal: Transl Psychiatry Date: 2019-05-23 Impact factor: 6.222
Authors: Tommy Aa Broeders; Alex A Bhogal; Lisan M Morsinkhof; Menno M Schoonheim; Christian H Röder; Mirte Edens; Dennis Wj Klomp; Jannie P Wijnen; Christiaan H Vinkers Journal: J Psychopharmacol Date: 2022-03-04 Impact factor: 4.562
Authors: Jonathan Chabert; Etienne Allauze; Bruno Pereira; Carine Chassain; Ingrid De Chazeron; Jean-Yves Rotgé; Philippe Fossati; Pierre-Michel Llorca; Ludovic Samalin Journal: Int J Mol Sci Date: 2022-08-11 Impact factor: 6.208